Answers are grounded in this paper and cite their sources.
Aim: To investigate the quality and characteristics of notifications on clinical drug trials to be conducted in children and adult healthy volunteers in Finland. Methods: All clinical drug trials involving children and healthy adult volunteers reviewed by the regulatory agency in Finland during the years 1992, 1994, 1996, 1998 and 2000 were analysed. The notifications were classified into the following categories: trials with no objection to commencement, number and type of questions raised, profile, phase and type of study, and trial design. Results: Altogether 352 trial notifications were analysed. Children were involved in 27 % of the trials and healthy volunteers in 73%. Most of the trials in children were phase III (53%), placebo-controlled studies with/without active controls (34%) while most trials involving healthy volunteers were phase I studies (70%) with a cross over, placebo-controlled design with/without active controls (42%). Investigations on new chemical entities (34 % children; 23 % healthy volunteers) and products that did not have marketing authorisation (55 % children; 63 % healthy volunteers) were most common. The regulatory agency had no objections or questions about 47 % (children) and 74 % (healthy volunteers) of the notifications. Respectively, 49 % (children) and 24 % (healthy volunteers) of the trials were permitted to begin after further clarification, while 3 % and 2 % were rejected. Most questions concerning the trials involving children dealt with the information provided to the study subjects (80%), while safety issues (47%) were most important in the trials involving healthy volunteers. Only a few of the trials (8 % children; 5% healthy volunteers) were later cancelled or discontinued.
No takes yet. Share an insight, caveat, or question.
Keinonen et al. (2003) studied this question.
Synapse has enriched 7 related papers. Consider them for comparative context: